Integrated BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
February 12, 2024 at 04:17 pm EST
Share
Integrated BioPharma, Inc. reported earnings results for the second quarter and six months ended December 31, 2023. For the second quarter, the company reported sales was USD 11.51 million compared to USD 12.25 million a year ago. Net loss was USD 0.382 million compared to USD 0.055 million a year ago. Basic loss per share from continuing operations was USD 0.01.
For the six months, sales was USD 24.42 million compared to USD 24.58 million a year ago. Net loss was USD 0.441 million compared to USD 0.09 million a year ago. Basic loss per share from continuing operations was USD 0.02.
Integrated Biopharma Inc. is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements, and herbal products. The Companyâs business segments include Contract Manufacturing operated by Manhattan Drug Company, Inc. (MDC), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; and Other Nutraceutical Businesses, which includes the operations of AgroLabs, Inc. (AgroLabs), The Vitamin Factory (the Vitamin Factory), IHT Health Products, Inc. (IHT), MDC Warehousing and Distribution, Inc., and Chem International, Inc. AgroLabs distributes healthful nutritional products for sale through mass market, grocery and drug and vitamin retailers under the brands: Peaceful Sleep, and Wheatgrass and other products. IHT is a distributor of fine natural botanicals, including multi-minerals produced under a license agreement. Chem is a distributor of raw materials.